Revolution Medicines Showcases Pipeline Progress and Phase 3 Trials Targeting RAS-Driven Cancers
I'm PortAI, I can summarize articles.
Revolution Medicines Inc. has updated its clinical pipeline for RAS-addicted cancers, reporting over 2,500 patients treated with RAS(ON) inhibitors. The company is conducting or planning eight Phase 3 trials for drugs including daraxonrasib, zoldonrasib, elironrasib, and RMC-5127, targeting pancreatic, non-small cell lung, and colorectal cancers. Daraxonrasib has shown promising results in monotherapy and in combination therapies. Ongoing trials for non-small cell lung cancer and completed enrollment for pancreatic cancer are noted. The full presentation is available via a provided link.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments